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Abstract 
 
Context: Psoriasis and atopic dermatitis are common chronic skin diseases associated with Quality-of-
Life reduction. There are numerous psychoeducative programs as adjunct to office-based care 
influencing self-management and quality-of-life. “Haut-Tief” is a model of such a multidisciplinary, 
psychoeducative intervention for Psoriasis and Atopic dermatitis.  
 
Objective: The aim of this study was to explore the acceptance of the “Haut-Tief” program in Swiss 
Psoriasis and Atopic dermatitis outpatients, if it is applicable and if potential benefits can be found.  
 
Study Design, Setting and Participants: We conducted a randomized-controlled trial with 17 
outpatients at the Department of Dermatology, University Hospital Zürich, Switzerland between October 
2012 and June 2013. 
 
Intervention: The intervention group received the intervention “Haut-Tief”, a multidisciplinary program 2x 
weekly for 9 weeks including dermatological and psychological education, stress-reduction, life-style 
information, next to regular office-based care and follow-up visits. The control group received the regular 
office-based care and follow-up visits. 
 
Main Outcome Measure: Dermatological (DLQI, Skindex29) and generic (SF-36: Mental Component 
Summary/ Physical Component Summary, EQ5D, EQ VAS) Quality of life assesments. 
 
Results: Patients were enrolled and the intervention, follow-up visits were completed. The enrollment-
rate was 21% over a 3 months’ recruitment period. The multidisciplinary content of the program was well 
accepted. There were no drop-outs in the intervention group. The Quality-of-Life-reduction in our patient 
population reached similar, moderately impaired levels as reported in other Quality-of-Life studies (DLQI 
scores in literature 6.43-12.3 for Psoriasis and Atopic dermatitis). In DLQI, Skindex29, SF36 and EQ5D, 
EQ VAS measurements no differences were observed after the intervention or during follow-up. 
 
Conclusion: Patients from the university outpatients’ clinic were interested in attending a 
multidisciplinary, intense intervention. While quantitative outcome was limited by small sample size, 
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qualitative outcome showed a need for and a benefit by such an intervention. The model is applicable; 
however, more repetitions with more patients are needed to show an effect on Quality-of-Life tools. 
Widened recruitment-modes could address a larger population and enhance participation.  
 
Abstract word count: 319 
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Abbreviations 
 
 
AD Atopic Dermatitis 
BDI Beck Depression Inventory 
BMI Body Mass Index 
COPD Chronic Obstructive Pulmonary Disease 
DLQI Dermatologic Life Quality Index 
EASI Eczema Area and Severity Index 
EQ5D Euro-Qol 5 Dimensions 
EQ VAS EQ visual Analogue scale 
EUROPSO European Federation of Psoriasis Patient Associations 
ISCED International Standard Classification of Education  
OR Odds Ratio 
PASI Psoriasis Area and Severity Index  
PDI Psoriasis Disability Index 
Pso Psoriasis 
QoL Quality of Life 
QoLIAD Quality of Life Index for Atopic Dermatitis 
SF36-MCS Short Form 36 mental component summary 
SF36-PCS Short Form 36 physical component summary 
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Introduction 
Intervention 
Curing a skin-disease involves more than administering the correct pill or cream. There are many factors 
which contribute to good health: genetic vulnerability, environmental factors, concurring bacterial or viral 
infections and other factors such as stress, lifestyle, emotional well-being, social factors (familial setting, 
economic well-being, access to health-care, community-life) which all have an impact on health. Apart 
from the psychosocial stress patients have to struggle with time-consuming and distressing treatments 
[14]. Therapy of psoriasis (Pso) and atopic dermatitis (AD) consists of multiple components as daily 
emollient use, antibacterial therapy, anti-inflammatory therapy and antipruritic therapy [5]. Adhering to 
therapy is demanding for a patient with Pso/AD. Torrelo [18] showed that only 14.9% of 155 patients with 
AD did follow their topical therapy regime prescribed by their dermatologist in a correct and compliant 
manner.  
Therefore, all these aforementioned factors are contributors to good health which is why it is important to 
recognize the factor lacking, and take appropriate action to remedy to that. Being capable of dealing with 
acute attacks of chronic skin disease, knowing which available therapies to use are all strategies which 
allow to better cope with chronic skin-disease.  
However, in the regular office based care there is not enough space to impart such practical and 
theoretical knowledge to the patient. Therefore, this standard treatment could be complemented by 
educational programs, which train the patient to cope with the disease and impart knowledge about 
dermatological therapies.  
Based on an educational/stress-reducing program for patients with Pso/AD developed in Ghent by 
Lambert and Bostoen [1,2] a helvetized, modified version –“Haut Tief”- was proposed in Zürich. This 
program provided a range of support activities and educational training which helped the patient by 
allowing her/him to learn about her or his illness, and what factors to consider in order to enhance the 
healing and coping process. 
Multiple studies investigating such educational and behavioral interventions on skin diseases (especially 
Pso and AD and chronic pruritus) have been performed in recent years. The interventions aimed to 
motivate the patients to better follow and adhere to their treatments and also enhance their Quality of Life 
(QoL). The concept of QoL reflects the impact of the chronic disease on the patient’s emotional, social 
and physical well-being. QoL has become, next to clinical severity, an important outcome measure for 
interventions in skin and chronic diseases. Protocols of these interventions vary from offering e.g. 
information about therapy-management by text messages [4], short online or DVD instructions [4,6], 
single sessions with nurses about skin care[3,4] to multiple sessions [9] or multidisciplinary, stress and 
life-style addressing or even multiple weeks lasting interventions[1,2,7,10]. 
It is worth noting that these approaches are used in other chronic disease management programs [39] 
such as for asthma bronchiale, diabetes mellitus, chronic obstructive pulmonary disease (COPD), 
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coronary heart disease or cancer. These chronic conditions have an increased prevalence of QoL-
reduction and psychiatric symptoms such as depression [14,39]. Acknowledging the psychological impact 
of the chronic condition on mental health in the disease management leads to a better disease control 
[39]. In addition these interventions promoted education, lifestyle factors and stress-reducing techniques 
resulting in an improved QoL and self-management. [37-43]. Mancuso [39] found a QoL improvement by 
an educational workbook with repeated motivating telephone calls in asthma. Vadstrup [40] investigated 
the effect of an educational program on clinical parameters and QoL in a group based versus individual 
based intervention for diabetes mellitus (18weeks, weekly). Mc Kee [40] found QoL improvement after a 
cardiac rehabilitation program of 6 weeks, 3x weekly. Generic QoL instruments allow a comparison of 
various interventions across different diseases and enable the interdisciplinary exchange of positive 
experiences. 
To our knowledge, no educational programs for Pso/AD have been tested and implemented so far in 
Switzerland. Because of positive experience in skin and other chronic diseases we aimed to implement 
such a psychoeducative intervention in Swiss dermatology outpatients. We offered “Haut-Tief” as such an 
intervention. Patients benefited from a multidisciplinary educational program combining support and 
disease specific information with cognitive educational sessions, stress-reduction techniques and skin 
workshops [1].  
The concept was developed and implemented by the department of dermatology in Ghent [1,2] where the 
intervention was added to standard treatment. Two sessions (2-3h) were offered per week for 12 weeks 
in Ghent. Lambert [1] showed in a pilot trial including multiple chronic skin diagnoses improvement in all 
QoL-instruments [Dermatology Life Quality Index (DLQI), Psoriasis disability Index (PDI), Quality of Life 
Index for Atopic Dermatitis (QoLIAD), Skindex29]. Bostoen [2] showed in the following randomized-
controlled trial (explicit Pso and AD) an improvement in QoL, psychiatric comorbidity as well as clinical 
severity for Pso. Because of its positive outcome and the holistic approach, we considered the concept of 
being appropriate for Swiss Pso/AD patients. We adapted the program from Ghent naming it “Haut-Tief”. 
Due to patients and trainers’ availability a study period of 9 weeks, twice weekly, was chosen. It has been 
the first exploration of such an intervention in Switzerland. 
Secondary Endpoints  
The role of physical, psychological and social factors in patients’ distress is evident. However, psychiatric 
disorders (e.g. anxiety and depression) are frequent among subjects presenting with skin diseases [15]. 
The prevalence for psychiatric symptoms (as sleep disorders, concentration, depression, activity, self-
concept) was 26% in psoriasis and 27% in dermatitis patients in a cross-sectional study with 2186 
dermatological patients [15]. The psychiatric comorbidity is indeed associated with a QoL-reduction. 
Picardi [15] reported an odds ratio of 2.4 for having a psychiatric comorbidity in case of a moderately 
increased Skindex29 score. Evers [20] found that 20%/13% of Pso/AD-patients had the same or higher 
scores on tools measuring depression and anxiety like outpatients actually diagnosed with depression or 
anxiety. A systemic review by Rasmussen [14] compromised 19 studies with patients` experience of 
living with Pso. Rasmussen found also an increased number of Pso patients with depression and anxiety 
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in 4 of these studies. Based on this analyses Rasmussen concluded that a multidisciplinary 
psychoeducative approach is needed to support these patients. In our study, depression as a psychiatric 
symptom was measured by the Beck Depression Inventory (BDI). Finally, the clinical severity was also 
captured by measuring the PASI for Pso and EASI for AD. 
Qualitative Feedback/ Enrollment Rate and Participation 
To capture further aspects influenced by our intervention, we collected the patient’s feedback 
(intervention group) in a feedback session and by an open-question “evaluation sheet”. The enrollment 
rate was recorded. 
Against this background, we conducted an explorative trial in Swiss Pso and AD outpatients to 
investigate QoL following the educative program “Haut-Tief” using different QoL instruments as primary 
endpoints. As secondary endpoints, we measured the symptom of depression as well as clinical severity 
and collected patients’ feedback. Furthermore, we determined in this explorative study acceptance and 
applicability of the program in Swiss outpatients.   
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Materials and Methods 
Instrumentation 
For primary endpoints, the following self-administered QoL-questionnaires were used: DLQI, Skindex29, 
SF36 and EQ5D with EQ VAS. 
For secondary endpoints, the depression as a psychiatric symptom was evaluated by using the BDI. 
Clinical Severity was measured using the PASI for Pso and EASI for AD.  
At the end of the program patients were asked for oral feedback in a feedback-session and for written 
feedback in an evaluation-sheet with open questions. The enrollment rate was recorded.  
Study Design 
We conducted a prospective, randomized-controlled trial at the Department of Dermatology, University 
Hospital Zürich, Switzerland, to explore the effects of a psychoeducative intervention on QoL, 
depression, clinical severity and patients’ feedback in Pso as well as AD outpatients. The trial was 
conducted between October 2012 and June 2013.  
In this study, the intervention group was enrolled in the “Haut-Tief”-program and benefited from this 
educational intervention. Additionally, topical therapy alongside with conventional office-based 
dermatological consultations was continued. The control group received the usual topical therapy and 
conventional office-based dermatological consultations. The patients of the intervention and control 
group were assessed and completed various questionnaires at 4 time points; before the intervention 
(baseline), after intervention (3 months), 6 months and 9 months after baseline. A patient was considered 
to have completed the study when all 4 appointments were visited and the questionnaires were returned. 
No blood tests or laboratory analysis were needed.  
Patients 
Inclusion and Exclusion Criteria 
The inclusion criteria were the diagnosis of Pso or AD in outpatients with a continuous or recurrent need 
of emollient and/or steroid therapy. Patient age was over 18 years. The exclusion criteria were systemic 
anti-inflammatory medication and severe illnesses. 
Recruitment 
To identify eligible patients, the daily appointment schedule of the outpatient clinic was reviewed for 
patients with Pso and AD. Diagnosis was confirmed by a dermatologist. While these patients were 
attending their regular dermatological consultation, they were assessed for inclusion and exclusion 
criteria by a sub-investigator and informed about the study. A patient-information was handed out. 
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Interested patients received an informed-consent and a study visit was scheduled. At the initial study visit 
baseline data was obtained, a clinical examination was performed and the QoL questionnaires were 
handed out. 
Randomization 
At the end of the initial screening visit patients were randomized into the intervention or control group The 
randomization sequence was computer-generated with an allocation ratio of 1:1. Patients opened a 
sealed envelope with an allocation to either the intervention or the control group.  
Primary Endpoints  
The profound impact of chronic skin diseases on the patients’ QoL has received much attention in the last 
years [2]. Multiple factors are reflected in this concept of QoL [14,1,2]. QoL compromises the influence of 
the visible skin disease on the patients’ physical, social and psychological well-being. The substantial 
physical burden in skin diseases such as pain and itch next to highly visible symptoms affect the patients’ 
everyday work and social activities as well as self-perception [12]. Even when taking therapeutic 
decisions in clinical practice the QoL is relevant [29]. Clinical severity alone, i.e. measured by Psoriasis 
Area Severity Index (PASI) / Eczema Area Severity Index (EASI) is not sufficient since it is not reflecting 
psychosocial difficulties and underestimating the severity of skin-disease [12,29]. Instruments quantifying 
QoL (skin-disease specific and generic QoL) are therefore increasingly part of clinical research. Various 
instruments have been validated [22,24,25,29 ,33].  
In our study, the following QoL instruments were used: DLQI, Skindex29, Short-Form 36 (SF-36), 
EuroQoL-5Dimensions instrument (EQ5D), EuroQol Visual Analogue Scale (EQ VAS).  
DLQI is a skin-disease specific instrument being the most widely used questionnaire in dermatological 
research as well as in clinical practice [29]. It contains 10 questions concerning the patients’ symptoms 
and feelings, personal relationship, leisure daily activity, work and school and treatment [1,22]. On basis 
of this score QoL-impairment can be classified as small, moderate, very large and extreme. The DLQI is a 
brief and simple to use instrument. Another advantage is the broad evidence for validity [22]. However, it 
has limitations such as a focus on disability [22,29] and limited sensitivity to change due to a statistical 
ceiling effect [29].  
 
Additionally, we used Skindex29 being a more sensitive instrument for the emotional well-being [2] than 
the DLQI. Skindex29 consists of 29 questions divided in three scales assessing each the burden of 
symptoms, social functioning and emotional state, respectively [1]. It has been developed as a more 
sensitive outcome measure in clinical trials and to detect changes in the QoL over time [24].  
 
Generic QoL instruments give an overall description of the health-related QoL. They are not disease 
specific and can be used across various diseases. These general QoL instruments allow a comparison 
between different diseases as well as to the normal population [32]. Quantifying the impact of the burden 
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of disease helps to understand if patients suffer from QoL impairment more than the normal population 
and to which disease it is comparable.  
The SF-36 is such a generic QoL-instrument used in skin diseases [28,29] and other chronic conditions 
as diabetes, asthma or coronary heart disease. Comprehensive clinical and epidemiological data is 
available [28]. The advantage of the SF36 is a broad validation for skin diseases [28,29] and an 
extensive data set to compare with. The SF36 offers also a more emotionally oriented measurement 
being a good completion to the disability focused DLQI [2,22]. The SF36 includes 36 questions 
concerning 4 dimensions of mental health (Vitality/ Social Functioning/ Role-Emotional/ Mental Health) 
and 4 dimensions of physical health (Physical functioning/ Role-Physical/ Bodily Pain/ General Health).  
To describe better the general health-related QoL an additional instrument, the EQ5D with its Visual 
Analogue Scale, was introduced. The EQ5D describes the health state in the 5 dimensions of mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. Patients asses their impact on each 
dimension by recording if they have no, a small or an extreme impact, respectively. Additionally, patients 
rate their individual current health state on a Visual Analouge Scale, the EQ VAS.  
Numerous cross-sectional studies [11-18] give us references about the actual QoL-impairment in Pso 
and AD measured by these instruments. For patients with Pso Schöffski[16] found a moderately impaired 
mean DLQI in 184 patients. For patients with AD, Torrelo [18] found a mild impact on QoL in DLQI in 141 
adults and Kim [18] found a moderate impact in 147 AD patients. QoL-impairment in Pso and AD is 
furthermore reflected in the Skindex29. Using the Skindex29 Chren [24] found a severe to moderate 
impairment in the three scales for Pso as well as for AD. Even when altering to generic QoL instruments 
as the SF36 the evidence stays in line with the prior findings. In 283 Norwegian Pso patients QoL was 
significantly lower than normal population [13]. Because of the varying methodology of the QoL-studies, 
the European Federation of Psoriasis Patients Association (EUROPSO) presented definitive evidence 
when gathering data from 18.386 Pso –patients in 7 European countries [12]. Using the Psoriasis 
Disability Index (PSI) as instrument, EUROPSO reported a large QoL-impairment in this patient group.  
Intervention 
The educational intervention consisted of educational sessions carried out by an interdisciplinary team of 
trainers including dermatologist, dermatologic nurse, pharmacist, psychologist, dietician, philosopher, 
training expert, meditation and yoga teacher. The educational program was running 9 weeks, during 
which lessons were given twice a week, on evenings. Patients of the intervention group benefitted 
from various program activities as specific information sessions on skin disease conditions and their 
mechanisms, symptoms, prognosis and treatment (dermatologists [2x1h], dermatological nurses [2x1h], 
pharmacist [1h]). Stress reduction techniques through sport sessions (physiotherapist [9x1h]), yoga 
classes [8x1h] and mindfulness meditation [3x2h] helping to cope with the symptoms such as itch and 
pain were offered. Most importantly, information sessions on life-style habits which influence skin disease 
were given. These included dietary advice by a nutritionist (2x1h) and educational sessions on sleep. 
Counseling for substance abuse (by a psychiatrist [1h]) was given. A  single smoking-cessation 
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consultation was offered but was optional. Lessons on psychodermatology or the effect of the psyche 
on chronic dermatoses (psychologist [1x2h]) as well as practical philosophy lessons (1x2) helped 
patients to change their attitude towards their disease. Sessions were held by eight professionals and 
were carried out in fitness as well as lecture facilities at the University Hospital Zürich. The detailed 
timetable is provided in the supplementary figure 2.   
 
Demographics and Baseline Characteristics 
A sociodemographic and clinical questionnaire was completed at baseline (age, dermatological and 
medical comorbidities, date of skin-disease diagnosis, duration of the disease, Body mass Index (BMI), 
education level) 
The classification of the education level followed the International Standard Classification of Education 
(ISCED) levels: low (lower secondary corresponding <10th grade), medium (upper secondary 10th-12th 
grade/ apprenticeship), high (post-secondary non-university/university education). 
 
Primary Endpoints 
Data were collected at baseline, month 3-, month 6- and month 9 follow-ups.  
 Dermatological Quality of Life (DLQI and Skindex29)  
Dermatological QoL was assessed at baseline and during follow-up (at 3,6 and 9 months) in the 
intervention group and control group. 
The DLQI is a validated, dermatology-specific quality of life instrument which is commonly used in 
dermatology in research as well as in clinical practice. Five aspects of the patients’ QoL (the patients’ 
symptoms and feelings, personal relationship, leisure daily activity, work and school, treatment) are 
investigated in 10 questions. Each question is rated on a four-point scale and a sum scores can be 
calculated. Following the categorization published by Hongbo [23], scores ranging from 2-5 show a small, 
scores 6-10 a moderate, scores 11-20 a very large and scores 21-30 an extremely large effect on QoL. 
The Skinex-29 is as well a validated, frequently used tool in research. It determines self-reported, skin 
dependent QoL. The Skindex29 consists of 29 questions and measures three dimensions of QoL in three 
separate scales: “Symptoms (7 items)”, “Emotions (10 items)”, “Functioning (12 items)”. Each dimension 
is represented in 0-100 scale with high values representing higher impairment. A mean value of these 
separate three scales was determined. For categorization, we followed the scale published by Nijsten et 
al. [26]. Nijsten categorized QoL-impairment in a very little (0-5)/ a mild (6-17)/a moderate (18-36)/ a 
severe (37-100) impairment.  
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Generic Quality of Life (SF 36, EQ5D, EQ VAS) 
Generic QoL was assessed at baseline and during follow-up (at 3, 6 and 9 months). SF36 and EQ5D 
including the EQ VAS are frequently used in research, self-reported QoL-tools. SF 36 has been validated 
for assessing QoL in dermatological diseases [29,29] and EQ 5D with its EQ VAS in the general 
population [33]. The SF36 contains eight main aspects of QoL determined in 36 questions. The eight 
aspects of QoL are Physical functioning/ Role-Physical/ Bodily Pain/ General Health/ Vitality/ Social 
Functioning/ Role-Emotional/ Mental Health. Each aspect can be determined separately and transformed 
in a 0-100 scale with 100 being the best health. The aspects can be also summarized in the mental 
component score (SF36-MCS) (Vitality/ Social Functioning/ Role-Emotional/ Mental Health) and the 
physical component score (SF36-PCS) (Physical functioning/ Role-Physical/ Bodily Pain/ General 
Health). Component scores as well as the single aspects of QoL can be compared to the normal 
population thanks to broadly available data [27]. 
The EQ5D is shorter, simpler and consists of 5 Questions representing 5 dimensions of QoL(mobility, 
self-care, usual activities, pain/discomfort, anxiety/depression). For each question the patient can choose 
one of three levels of severity (no problem, some problems and extreme problem). For the evaluation, we 
chose the multiplicative model because of its sensitivity. The descriptive EQ5D is complemented by a 
Visual Analogous Scale, the EQ VAS. In the EQ VAS patients estimate their current state of health on a 
continuous 0-100 scale with 100 being the best health.  
Secondary Endpoints  
Depression Severity (BDI) 
The BDI is a self-reporting questionnaire (21 questions) measuring depression. It is widely used in clinical 
practice and research. For each question, there is a four-point scale ranging from 0 to 3. The total score 
is calculated by adding up the points of each question.  For the interpretation, we used the classification 
of the published BDI-Manual [34]. Patients were categorized as having no depression (0-8 points)/ 
minimal (9-13 points)/ mild (14-19 points)/ moderate (20-28) /severe(29-63points) depression [34]. The 
BDI was used to detect accompanying depression as a psychiatric comorbidity in our patient population. 
Clinical Scores (PASI/EASI) 
PASI describes the severity of Pso on the human skin and is influenced by 4 parameters. These 
parameters are assessed by clinical examination of Pso specific skin lesions. For examination, the 
whole-body surface is separated in 4 regions: head, trunk, upper extremity, lower extremity. For each 
region, 3 parameters describe the Pso lesions: (i) intensity of redness, (ii) severity of scaling, (iii) 
thickness. A Sum score is multiplied with the affected body surface that is categorized in a scale from 1 
(<10% body surface) to 6 (90-100% body surface) for each region. A high PASI indicates severe Pso. 
EASI score is a tool used to measure the severity and extent of AD and is a useful and objective follow-
up tool. It measures the intensity of redness (erythema), the thickness (induration, population, and 
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oedema), scratching (excoriation) and lichenification (lined skin) of the eczema in 4 body regions (head, 
trunk, upper extremity, lower extremity). 
Qualitative Feedback (Mutual Feedback Session, Open Questions) 
Patients’ feedback was part of the collected data. The patients’ feedback was gathered as oral feedback 
in a feedback-session and as written feedback in evaluation sheets with generic as well as intervention- 
specific questions. Comments from oral feedback as well as written feedback were sorted by their 
contents and addressed topics. The topics were assigned to two dimensions, the dimensions of physical 
burden and psycho-social burden of disease. This structure presented an overview about what topics 
were concerning the patients and to what extends the physical or the psycho-social burden of disease 
affected them. 
Enrollment Rate and Participation 
The number of patients who were screened was documented in a screening-log. Furthermore, the 
numbers of patients who initially signed the informed-consent and who actually commenced the 
intervention and the follow-up visits were registered. 
 
Statistical Analysis 
We conducted a pilot trial and explored if our intervention effected primary and secondary outcomes. A 
paired t-test was conducted to identify differences in primary and secondary outcomes after the 
intervention and after the follow-up within each group. The results are presented as boxplot for the 
intervention and the control group separately. Each box represents the pooled results measured at one-
time point. Baseline data with means and standard deviation is shown separately. The 95% confidence 
intervals are presented graphically in the supplementary data. We used unpaired t-tests to compare data 
from intervention and control group at baseline, after 3 months, and after 9 months. The changes within 
the intervention group were compared to the changes within the control group using an unpaired t-test. A 
p value of 0.05 and less was considered significant. IBM SPSS Statistics, Version 21, Armonk, NY, was 
used to calculate statistics. 
Study Approval 
The study was approved by the local ethical committee (registration number KEK-ZH-Nr. 2011-0458) and 
registered with a public clinical trials registry (Clinicaltrials.gov NCT02205593). 
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Results 
85 patients with Pso and AD were eligible and informed consent was handed out. 65 declined to 
participate (time constrains, lack of interest) and two were excluded due to a new decision for a systemic 
therapy. 18 patients with Pso and AD were recruited from the out-patient clinic at the Department of 
Dermatology of the University Hospital Zürich from July 2012 to September 2012. The 18 patients were 
randomized with 9 being allocated to the intervention group and 9 to the control group. One patient in the 
intervention group declined participation after being randomized because of time constrains. In the control 
group, one patient did not return the questionnaires at baseline after being seen in the baseline study 
visit. 16 patients were available for baseline analysis.  
 
Demographics and Baseline Characteristics 
Sociodemographic and clinical data are shown in table 1.  
Mean age in the intervention group and control group was 38.2 (±14.1) and 35(±9.8), respectively. Mean 
duration of disease was 19.3 (±16.6) and 7.5 (±5.2) years in intervention and in control group, 
respectively. In the intervention group, 75% had a high and 25% a medium education level. In the control 
group, 50% had a high, 25% a medium and 25% a low education level.  
The baseline data for the disease specific (DLQI and Skindex29) and generic (SF-36, EQ5ED, EQ VAS) 
QoL questionnaires as well as BDI were collected in both groups. 
The DLQI was moderately elevated in both groups following the categorization by Hongbo [23]. Mean 
DLQI scores were 8.1 (SD ±6.52) and 9.1(SD ±5.4) in the intervention and control group, respectively. 
The Skindex29 was moderately elevated in the intervention group and severely elevated in the control 
group following Nijsten [26]. Mean Skindex29 scores were 28.3 (SD ±5.6) and 47 (SD ±7.1) in the 
intervention and control group, respectively. The difference for mean Skindex29 between the intervention 
and control group was not significant (p=0.059). 
Analyzing the SF36 we found a SF36-MCS (consisting of the levels Vitality/ Social Functioning/ Role-
Emotional/ Mental Health) of 69.14 (SD± 10.95) for the intervention group and of 50.4(SD ±26.7) for the 
control group at baseline. Mean SF36-PCS (levels: Physical functioning/ Role-Physical/ Bodily Pain/ 
General Health) was 86.6(SD±5.2) for the intervention group and 67.1 (SD±26.8) for the control group at 
baseline.  
The EQ5D score (multiplicative model) was 88.3(±13.2) and 65.1(±21.2) for the intervention and control 
group, respectively. The EQ VAS score was 77(±10.8) and 58(±21.9) for the intervention and control 
group, respectively. 
A statistical comparison of baseline scores between the intervention and control group was performed for 
DLQI, Skindex29, SF36-MCS, SF36-PCS, EQ5D and EQ VAS. Our control group showed higher scores 
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in DLQI (p= 0.7), in Skindex29 (p=0.059), SF36-MCS (p=0.089), SF36-PCS (p=0.063) as well as in EQ5D 
(p=0.012) and in EQ VAS (p=0.045). 
BDI revealed 2 patients with mild depressive symptoms in the intervention group. In the control group, we 
found 4 patients with mild and 2 with moderate depressive symptoms. 
Clinical severity measured by PASI for Pso was 3.3(±1) and 3.4(±2.2) in the intervention group and 
control group, respectively. EASI for AD was 1.9(±1.1) and 4(±3) in the intervention group and control 
group, respectively.  
 
Primary Outcomes 
Dermatological Quality of Life (DLQI and Skindex29)  
DLQI and Skindex29 scores are shown in figure 2, panel A and figure 2, panel B, respectively.  
No differences were found for DLQI and Skindex29 after intervention or follow-up (at 3 months, 6 months, 
9 months), neither in the intervention nor in the control group. 
Generic Quality of Life (SF 36, EQ5D, EQ VAS) 
SF36 scores for the SF36-MCS and SF36-PCS are shown in figure 3, panel A and figure 3, panel B, 
respectively. 
No differences were found for SF 36 (MCS and PCS), EQ5D and EQ VAS after intervention or follow-up 
(at 3 months, 6 months, 9 months), neither in the intervention nor in the control group.  
Secondary Outcomes 
Depression Severity (BDI) 
BDI scores are shown in figure 4.  
No differences were found for BDI after intervention or follow-up (at 3 months, 6 months, 9 months), 
neither in the intervention nor in the control group.  
Clinical Scores (PASI/EASI) 
EASI and PASI scores are shown in figure 5, panel A and figure 5, panel B. 
For clinical disease severity, no differences were found in EASI and PASI during the follow up, neither in 
the intervention nor in the control group.  
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Qualitative Feedback (Mutual Feedback Session, Open Questions) 
The patients’ feedback is shown in table 2 and 3. 
When asking patients for generic feedback about the program, the topics of being motivated by the group, 
the long duration and the diversity of topics offered (holistic approach) were mentioned. Two patients 
have been already practicing alternative relaxation techniques. These two stated that the exhaustion was 
high for the gained experience. Six patients had no experience with mediation and yoga. They 
appreciated the possibility to test multiple relaxation techniques. The group interaction was reported as 
being positive. The sessions’ contents and information was appreciated by all patients.  
Patients were concerned about understanding the skin-pathology, receiving information on the disease 
and their personal management of daily stress (dimension of the physical burden of disease). Patients 
mentioned feeling ashamed because of the visibility of skin disease, helpless, afraid of being rejected by 
healthy individuals and consecutively indicated a reduced self-esteem (dimension of the psychological 
burden of disease). Further details are provided in table 2 and 3. 
 
Enrollment Rate and Participation 
Out of 85 eligible patients 18 were interested in participating. One patient of the intervention group 
dropped out before the baseline visit due to organizational difficulties. We calculated an initial enrollment 
rate of 21%. All 8 patients in the intervention group completed the intervention and follow-up visits (0% 
lost to follow-up). In the control group, three patients were lost to follow up along the study period (33% 
lost to follow-up). 
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Discussion 
Data will be discussed as followed.  
Intervention/Study Design 
Patients     
• Recruitment 
• In-/Exclusion Criteria 
Demographics and Baseline Characteristics 
• Age 
• Literacy Level 
Prim. Outcomes at Baseline 
• DLQI 
• Skindex29 
• SF36 
• EQ5D 
• EQ VAS 
• Differences between groups 
Sec. Outcomes at Baseline 
• Depression severity 
• Clinical severity 
Enrollment Rate and Participation 
Prim. Outcomes at Follow-up  
• DLQI/Skindex29/SF36 
Sec. Outcomes at Follow-up   
• Depression Severity/Clinical Severity 
 
Qualitative Feedback 
Enrollment Rate and Participation 
Limitations 
Statistics 
Conclusion 
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Chronic skin disease has a profound impact on the patients’ QoL [1,14,12]. The visibility of the skin 
disease as well as the experienced physical pain, itch and also fatigue [20] lead to a psychosocial 
impairment, which in turn results in a QoL impairment.  
The clinical outcome and QoL in chronic skin-diseases is likely to be dependent on environment and 
lifestyle. The negative effects of smoking, drinking, poor eating habits, lack of exercise, and 
psychological stress have been well documented [1,2]. In light of this, adopting a preventive and/or 
curative attitude towards improving these life-style factors may constitute a big step in improving chronic 
diseases both in a direct manner, but also in an indirect manner by improving strategies of self-
management. 
Patients’ self-management can be supported in a holistic manner by education about the skin diseases 
and by stress-reduction as well as improvement of lifestyle factors. Therefore, educational interventions 
have been proposed as an adjunct to routine clinical practice [4] in dermatology. Several educative 
programs [3,4,5,7] for skin diseases as chronic pruritus, Pso, AD or vitiligo have been put forward and 
experienced as a valuable addition to clinical treatment by patients [4]. At the Department of dermatology 
University Hospital Zurich, there have been no such educative interventions so far. A concept for a 
multidimensional, psychoeducative disease management as practiced abroad [1,8,9,10] was not 
implemented, yet. Being confronted with positive QoL and clinical outcomes from several educative 
interventions for chronic skin-diseases [1,2,3,4,5] we have put forward research in this field of patient 
education.   
In the clinical practice QoL of the dermatological outpatient clinic at the University Hospital Zürich. 
questionnaires were handed out systematically to patients and the clinicians took QoL-scores in account 
when deciding about the patients’ therapies. However, specific interventions targeting psychological 
distress and supporting the patients’ adherence to therapy were not offered.  
We started an explorative investigation of the patient education program “Haut-Tief” in Swiss outpatients 
with Pso and AD. To our knowledge, this was the first multifactorial, psychoeducative program of such a 
design performed in Switzerland. Due to the positive outcomes in a pilot study by Lambert [1] the 
intervention was based on this concept. In a pilot study [1], QoL significantly improved after the 
psychoeducative intervention as revealed by validated questionnaires (DLQI, PDI, QoLIAD, Skindex29, 
BDI). Multiple inflammatory skin diseases were included. A following randomized controlled trial [2] for 
Pso and AD revealed a QoL improvement for Pso. Furthermore, the severity of psychiatric symptoms 
and clinical scores improved as well in Pso. These positive initial results [1,2] were encouraging for 
setting up a study to explore the impact on QoL and clinical efficacy of  this  intervention program on 
Swiss patients.  
 The educational program in Ghent consisted of 2-h sessions twice a week for 12 weeks. An 
interdisciplinary team of trainers was involved in the sessions (dermatologist; dermatologic nurse; 
pharmacist; psychiatrist; psychologist; dietician; philosopher; training expert; mindfulness and yoga 
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teacher). Sessions included activities giving practical and theoretical information on skin disease, Stress-
reduction techniques and information sessions on life style factors and psychodermatology [1]. 
Intervention/ Study Design 
The aim of our trial in Zurich was to explore the effect on QoL, acceptance by patients and applicability of 
the above-mentioned intervention in a Swiss outpatient setting. We took the opportunity to study the 
baseline QoL in our patient sample being recruited from the outpatients’ clinic at the department of 
dermatology, University Hospital Zurich. Comparison to multiple cross-sectional data gave us the 
possibility to understand the extend of the psychosocial burden of disease in our particular patient 
population. We chose a randomized-controlled design where one group was receiving an educative 
intervention as well as follow-up visits while the other group was only seen for follow-up visits. Our 
intervention was adapted to 9 weeks, twice a week due to trainers’ and patients’ availability. As primary 
outcome measures we used the following instruments. DLQI, Skindex29, SF36, EQ5D and EQ VAS. As 
secondary outcomes, we measured the depression severity by using the BDI and clinical severity by 
using the PASI for Pso and EASI for AD. Primary and secondary outcomes were measured at baseline, 
at 3,6 and 9 months’ follow-up. 
Patients  
In/Exclusion Criteria 
Pso and AD outpatients in Switzerland usually receive topical therapy. Indication for a systemic treatment 
with immunosuppressive agents (cyclosporine A, methotrexate or biologics) depends on the clinical 
severity and impairment in the QoL. For Pso indication criteria for systemic therapy are defined. Systemic 
treatment is indicated if PASI or DLQI score reach 10 according to internal guidelines. In our study 
patients receiving systemic therapy were excluded. Due to the exclusion of the severe cases our patients 
sample had a low disease severity. In the Ghent study, all patients were included (topical and systemic 
therapy, no therapy details were given). 
Recruitment 
Patients with Pso and AD were recruited from the outpatient clinic at the Department of Dermatology of 
the University Hospital Zürich. Preselection of eligible patients was possible due to available data from 
the internal hospital information system. In Ghent, patients were recruited from the Ghent University 
Hospital and additionally from patient advocacy groups and peripheral dermatologist. Noteworthy is the 
fact that 74% of the patients in Ghent were recruited by the latter two, patient advocacy groups and 
peripheral dermatologist. In comparison to our setting the majority of the patients in Ghent was recruited 
outside the outpatient clinic. More interested individuals could have been recruited in Zurich, if information 
about our program were provided by patient advocacy groups or peripheral dermatologists. 
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Demographics and Baseline Characteristics 
At baseline, age, dermatological and medical comorbidities, date of skin-disease diagnosis, disease 
duration, BMI and the education level were collected.   
Age/ Duration of Disease 
After randomization, we found differences in age and duration of disease between the intervention and 
control group. Age in the intervention group averaged 38.2 (±14.1) years, compared to 35(±9.8) years in 
the control group. More interesting for further evaluation of the QoL was the difference in disease duration 
between the groups. We observed a shorter duration of disease in the control group. Disease duration 
was 19.36 (± 16.6) years in the intervention group versus 7.5 (±5.2) years in the control group. Therefore, 
we experienced a situation in which the patients who had a longer experience with the skin disease were 
receiving an educative intervention. The control group which consisted of less experienced patients was 
not receiving any educative program. 
Literacy Level 
Another baseline characteristic obtained was the literacy level. The definition by the International 
Standard Classification of Education (ISCED) was followed and three levels of education were 
distinguished: low (lower secondary corresponding 10th grade), medium (upper secondary 10th-12th 
grade/ apprenticeship), high (post-secondary non-university/university education). Average education was 
high across the whole patient group. 75% and 25% of the intervention patients had a high and medium 
education level, respectively. Patients of the control group stated to have high, medium and low education 
level in 50%, 25% and 25%, respectively. Despite of offering the program to all patients in the outpatient 
clinic matching the inclusion criteria, the results suggest a selection of patients with a higher literacy level. 
Patients with a higher literacy level were more interested in the program. Investigation related patient-
information were potentially too complex.  
Primary Outcomes at Baseline 
The QoL in dermatology as well as other chronic conditions has been subject of continuous research in 
the past years [14]. It reflects the patients’ self-experienced emotional, social and physical well-being. 
The multidimensional concept [3] shows how the patient perceives her/his burden of disease [3,4]. 
Physical symptoms such as itch [20] or pain and fatigue impair the physical well-being. The skin-
symptoms as redness, severity of scaling, thickness, plaques are visible to the patients’ surrounding and 
are influencing the social function [14]. Therefore, the impairment of the emotional and social well-being 
is also a result of the of the skin disease [14]. Psychological distress in turn can trigger aggravation of the 
skin disease [20,50]. Hence, multiple factors contribute the disease severity the patient actually 
perceives her/himself. Evers [20] explored specific factors contributing to psychological distress in 
Pso/AD. Higher levels of fatigue, illness cognitions of greater helplessness and less perceived support 
were identified as contributing factors to psychological distress. In this context, QoL became an important 
outcome measure to consider both in clinical practice and dermatological research. When assessing the 
disease severity for therapeutic decision-making [29], attention should be drawn to the QoL additionally 
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to clinical severity measured by PASI and EASI. For this reason, the QoL was the primary outcome to 
measure effectiveness of our explorative investigation. 
DLQI 
DLQI is a widely used and easy to apply dermatology specific QoL instrument. It was moderately 
impaired in both groups [intervention: 8.1 (SD ±6.52) control: 9.1(SD ±5.4)]. The data of numerous QoL-
studies may serve as reference to our data. In Ghent, Bostoen [2] found a comparable, moderately 
elevated DLQI score in both groups [intervention 9,7 (± 6.0)], control 7,5 (± 5.0)]. Other studies enrolling 
both, Pso and AD patients, recruited from outpatient clinics showed the following results. Lundberg et al. 
[17] found a moderate DLQI impairment in 366 Pso/AD patients with a mean DLQI of 6.43(±5.81). Maroti 
found [11] a mean DLQI of 8.8 in 50 outpatients. Only Lambert [1] had a baseline population with a higher 
impairment [ DLQI in Pso 9.87 (±6.63) and AD 14.80 (±6.77)]. Mean DLQI values obtained from the Swiss 
patients taking part in this trial were comparable with the published data in other European countries. 
Skindex29 
Skindex29 was moderately elevated in the intervention group with 28.3 (SD ±5.6) at baseline. In the 
control group however, Skindex29 was elevated with 47 (SD ±7.1) at baseline. Consequently, it revealed 
a higher impairment in the control group than measured by DLQI. The QoL impairment in our control 
group was comparable to the pathologic scores at baseline reported in Ghent [2] [intervention 45.5 (± 
16.1), control 43.3 (± 17.7)]. Skindex29 is a more sensitive instrument for the emotional well-being [2] and 
has a higher sensitivity to measure disease related changes [2]. This capability could explain the higher 
impairment measured by Skindex29 compared to the DLQI result in the control group.  
SF36 
We found a psychosocial sub score (SF36-MCS) of 69.14 (SD± 10.95) and 50.4(SD ±26.7) in the 
intervention group and control group, respectively. The physical sub score (SF36-PCS) was 86.6(SD±5.2) 
and 67.1(SD±26.8) in the intervention group and control group, respectively. The German federal health 
survey [27] was available as a reference for normal scores. The SF36-MCS scores were 80 and 75 in 
men and women, respectively. For the SF36-PCS, normal scores of 78 and 73 were reported for men and 
women, respectively. Other studies using the SF-36 in dermatology as Lundberg and Wahl [17,13] found 
a SF36-MCS of 69.9 and 62.3 as well as a SF36-PCS of 68.1 and 64.0, respectively. Also Valdstrup for 
diabetes mellitus patients [40] as well as McKee for cardiology patients [41] showed similar values. In our 
patient group, we found a disparity between the SF36-MCS and the SF36-PCS score. There was a 
difference of 17.5 and 17.1 between the SF36-PCS and SF36-MCS in the intervention group and control 
group, respectively. We did not see such a disparity in all of the above-mentioned studies.  
EQ5D/ EQ-VAS 
EQ5D and EQ VAS showed a QoL impairment comparable to the above discussed findings.  
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Differences between Intervention Group and Control Group  
Despite randomization, relevant differences between groups were observed. Differences in the baseline 
data between the intervention and control group are listed in Tabl.1. Particularly, the QoL showed a 
higher impairment and the duration of disease was shorter in the control group.  
 
Secondary Outcomes at Baseline 
Depression Severity (BDI) 
Dermatological patients have an elevated prevalence of psychiatric symptoms, as anxiety or depression [15]. The 
physical symptoms impair the patient’s physical well-being and also influence the psychological health. 
For example, itch, the most prominent symptom in chronic skin disease [9], and pain are resulting from 
the chronic skin inflammation and are accompanying the patient constantly when therapy fails controlling 
the symptoms. Itch can cause sleep disturbances, agitation, depression and concentration problems [9] 
leading to psychological distress.  
We used the BDI to measure depressive symptoms as a psychiatric co-morbidity of the chronic skin 
disease. Results obtained, however, showed a variability in scores.  BDI scores ranged at baseline from 1 
to 17 and 0 to 29 in the intervention group and control group, respectively. The depression severity can 
be classified based on the absolutes score as no depression (0-8), minimal depression (9-13), moderate 
depression (14-28) and severe depression (29-63) [34]. Two patients the intervention group had a 
pathological BDI. However, In the control group six patients had a pathological score. The higher 
proportion of pathological scores in the control group gave again evidence for the higher psychosocial 
impairment in this group. The results of the BDI go in line with the elevated impairment we have already 
observed in the QoL instruments.   
Clinical Scores (PASI/EASI) 
Along with QoL, which is offering a patient-centered view of the burden of disease, there are clinical 
scores allowing an assessment of the disease severity on the skin. Theses scores are important for 
monitoring and as an outcome measurement in both research and clinical practice [33]. The PASI was 
developed as an easily applicable tool for the assessment of the inflammation in Pso. It became widely 
accepted in dermatology as it offers a simple, easy to determine score [33]. The PASI includes two 
components: the total body area affected and the intensity of key signs as redness, thickness and scaling 
in each of 4 body regions. The EASI is a modification of the PASI and adapted for AD [33]. 
We found a low clinical severity at baseline in both groups and both diseases (Pso and AD). PASI and 
EASI had similar values in both, intervention and control group.  PASI was 3.3 and 3.4 in the intervention 
group and the control group, respectively. In the outpatient clinic at the department of dermatology this is 
considered as a low impact and only scores beyond 10 are considered as sever. Also the disease 
severity measured by EASI in AD showed a low clinical severity with an EASI of 1.9 and 4 in the 
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intervention group and the control group, respectively. In Ghent, considerably higher baseline values 
were reported. Bostoen [2] observed a baseline PASI of 8,9 (± 4,3) 7,1 (± 3,8) in the intervention group 
and control group, respectively. EASI score reached 11,9 (± 10,9) and 10,4 (± 8,1) in the intervention 
group and control group, respectively.  No clinical scores from the pilot trial in Ghent were available.  
Primary and Secondary Outcomes at Baseline 
Hence, we observed a contrast between the clinical severity and the elevated QoL at baseline. We found 
for our patients a similar impairment in DLQI as Schöffski [16] found for Pso with a severe PASI score. 
Schöffski [16] reported for patients with a PASI of 13.5 (severe disease) a DLQI of 8.7, which is similar to 
our results. Rasmussen and Evers [14,20], studies coming from the field of QoL research, describe that 
QoL impairment does not correspond to the clinical severity. Evers investigated factors contributing to 
psychological distress in 248 Pso/AD patients and found that clinical severity had a minor impact on the  
psychological well-being. In contrast to Rasmussen and Evers, studies by Schöffski, Torrelo and Kim 
[16,18,19] found a rising DLQI score associated to rising clinical severity in Pso and AD patients. 
Enrollment Rate and Participation 
We looked at the enrollment in the program in order to understand if patients are willing to accept the 
offered program. Enrollment in our program was low with 18 patients enrolled out of 85 eligible patients. 
Reasons for not participating were time constrain, difficulties in organization and lack of interest. Similar 
enrollment-rates were published for other educative ore rehabilitation programs. Bjoernshave [45] did a 
prospective study on enrollment in a pulmonary rehabilitation program (2x weekly for 8 weeks) finding 
14% patients participating of all initially intended to be included. McDonall [4747] found an enrollment-rate 
of 11.9% out of all patients identified as eligible for a cardiac rehabilitation program. Out of 103 selective 
referrals to a medication therapy management clinic (counseling on the patient medication regimens)[47], 
68% had an initial contact and only 17% were enrolled. Our enrollment rate was comparable with data 
from the literature.  
Aiming to improve enrollment rates, more attention to the participants’ characteristics should be drawn. 
We found a high education level in our patient sample (medium or high education level in 100% of the 
intervention group respectively 75% in the control group). Despite of offering the program to all patients in 
the outpatient clinic matching the inclusion criteria, the results suggest a selection of patients with a 
medium to high education level by our voluntary recruitment method. A method to include more patients 
with a different background could be an automatic recruitment. Kimbro [49] found that automatic 
inscription to a diabetes health plans caused a 91% enrollment rate versus only 35% by voluntary 
enrollment. However, Kimbro did not find differences in the education level or income in between the 
automatic referral and voluntary referral group. Automatic referrals could be also a tool including patients 
of a younger age, shorter disease duration and higher QoL reduction. These patient groups could benefit 
from such altered recruitment method. However, the educative program is very time-consuming and 
builds on patient engagement. A high drop-out rate could be the effect of an automatic recruitment. 
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Therefore, using other channels for recruitment as through patient advocacy groups could be an 
alternative implementation.  
 
Primary Outcomes at Follow-up  
We assessed the acceptance of our program by patients and their benefit from the intervention. We 
explored the benefits for patients from primary and secondary endpoints and qualitative feedback. 
DLQI/Skindex29/SF36 
Mean scores for the DLQI, Skindex29 and SF36 did not show differences after the intervention or follow-
up. 
The small sample size of our exploratory trial should be taken in account when comparing our results to 
the one published in Ghent. In the pilot trial [1] mean DLQI moved from 9.87 and even 14.80 at baseline 
to 5.93 and even 8.47 after the intervention for Pso and AD, respectively.  In the randomized-controlled 
trial [2]  intervention  patients showed reduction in mean DLQI going from 8,0 at baseline to 4,8 at 3 
months, 4,7 at 6 months and 4,0 at 9 months follow-up. For AD no difference in DLQI was shown. 
Skindex29 did not show difference in our trial as well as in the randomized controlled trial in Ghent.  
The SF36-MCS and SF36-PCS did not show differences after the intervention or follow-up. However, it is 
noticeable that 100% of the SF36 sheets returned were entirely completed. There was more missing data 
when other self-administered questionnaires were used. 16 patients at baseline and 14 patients at the 3,6 
and 9 months’ follow-up returned their hand-outs (each with 6 questionnaires). In these 58 hand-outs 
which were available to us, 98%, 93%, 100%, 100% and 91% of the DLQI, Skindex29, SF36, EQ5D and 
BDI were completed, respectively. This finding indicated a good acceptance of the SF36 by patients. 
 
Secondary Outcomes at Follow-up   
The depression severity and clinical severity were measured as secondary outcomes after the 
intervention and after 6 as well as 9 months’ follow-up in both groups. A qualitative feedback 
provided information about the subjective benefit from the intervention. We recorded the 
number of drop-outs or subjects lost to follow-up to gain a better understanding about the 
general acceptance of the program.   
Depression Severity (BDI)/ Clinical Scores (PASI/EASI) 
There was no difference in BDI scores after the program or after the follow-up in the intervention and 
control group. However, one of the two intervention patients with a pathological result at baseline (14, 
mild depression) and at 3 months’ follow-up (20, moderate depression) scored 0 on the BDI at 6 months’ 
and 9 months’ follow-up.  
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Clinical scores did not show differences after the intervention or follow-up. Bostoen [2] showed mean 
PASI from 8,6 at baseline to 6,5 at 3 months, 6,0 at 6 months and 7,0 at 9 months. EASI for AD did not 
show a significant difference after the intervention. Comparing this data to our measurements, our 
patients had lower PASI scores than the lowest PASI score observed in Ghent. Because of the low 
burden of disease, it is difficult to detect alterations in clinical severity. 
Qualitative Feedback (Mutual Feedback Session, Open Questions) 
We explored the benefit for patients by collecting the patents’ feedback. Patients provided feedback about 
the intervention’s set-up and the sessions’ contents.  
The patients appreciated the holistic, multidisciplinary concept and expressed that they were profiting 
from the information’s quantity as well as quality. Also the possibility of exploring the diversity of stress-
reduction techniques was endorsed. Patients approved the multiple offers on information about skin 
pathophysiology and life-style. Better information enhances patients’ compliance and self-management 
[21]. A possibility could be measuring the patients’ compliance or self-management to gain more 
information. Patients also felt that the program was exhausting. Only one patient took advantage of the 
voluntary smoking cessation session.   
In patients’ feedback a benefit by perceived social support was expressed. The positive group interaction 
was an important positive advantage of our program. Patients mentioned being relieved by exchanging 
personal experience and meeting patients with similar burdens. Observing the social interactions, it would 
be of interest to understand the influence of the individual components on the QoL. In future studies, the 
sub scores of DLQI (Symptoms and feelings, Personal relationships, Leisure Daily activities, Work and 
School, Treatment), Skindex29 (emotional, social, physical) and SF-36 (8 scales) should be included in 
the analysis. 
Conflicting results about the group interaction were found by Vadstrup.  Vadstrup [40] compared the 
effect of a group based versus an individual setting in a multidisciplinary education program for diabetes 
mellitus II. Vadstrup found a decrease in “fatigue”, a sub score of the Diabetes Symptom Checklist, in 
both settings (p = 0.01, p < 0.01). Additionally, Vadstrup observed an improvement of the 
“Hyperglycaemia” sub score of the Diabetes Symptom Checklist (p=0.04), and in the “vitality” sub score of 
the SF36 (p=0.03) only in the individual setting.  
Enrollment Rate and Participation 
A possibility to understand if the program was accepted was to analyze the adherence to it. Lower drop-
out rates than in literature supported a satisfactory acceptance. In the intervention group, one patient 
resigned before baseline data was collected and all the other eight intervention patients finalized the 
intervention. In the control group 3 patients were lost to follow-up over the 9 months’ study period. 
Bostoen [2] and Lambert [1] found a higher drop-out rate of 9/25(36%) and 12/55(22%)  in each 
intervention group, respectively. In contrast to our results, Bostoen found less drop-outs, 4/25(16%), in 
the control group. Other studies found also higher drop-out rates than we did. McDonall at al. [47] had 
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only 66.8% of completers in a cardiac rehabilitation. Further cycles of the program are needed, in order to 
confirm our observation of low drop-out rates. 
Limitations 
Limiting was the small number of subjects included. A further limitation is, that therapy adherence and 
self-management were not explored. Furthermore, our patient population started with a low burden of 
disease, limiting the range of measurable improvement in our study.  
Statistics 
Descriptive statistics were performed. Due to the small sample size an interpretation of the results has 
limited validity. 
  
Conclusion 
In conclusion, patients were interested in in attending a multidisciplinary, intense intervention. 
Quantitative outcome was very limited. Qualitative outcome showed a beneficial effect on the social 
burden of disease. Physical training was not well received because of low physical burden of disease. 
Recruitment should be extended to other platforms as patient advocacy groups to meet the interested 
patient population. Effect on compliance and self-management should be recorded additionally to identify 
further effects.  Further intervention cycles will be organized in order to improve outcome analysis. 
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Table 1: Patient Characteristics at Baseline (month 0) 
 
Variables Intervention  
 
 
 Control               
n 
 
8 
   
9 
 
p 
Diagnosis n(%)                 
Psoriasis                             
Atopic dermatitis 
 
 
2 (25) 
6 (75) 
   
 
6 (67) 
3 (33)  
  
Gender n(%)                           
female                                     
male 
 
 
4 (50)4 (50) 
   
 
5 (56) 
4 (44) 
  
 
mean(±SD)   mean(±SD)   
Age [years] 
38.2 (±14.1)   35 (±9.8)   
Duration of disease [years] 19.3 (±16.6)   7.5(±5.2)     0.1 
Education  
low/medium/high [%] 
75/25/0   50/25/25   
 
      
BMI [kg/m2] 21.5 (±2.7)   24.8 (±5.1)  0.123 
EASI  1.9 (±1.1)   4.0 (±3.0)    0.152 
PASI 3.3 (±1)   3.4 (±2.2)  0.946 
 
DLQI 
 
8.1 (±6.5)   9.1 (±5.4 )  0.742 
Skindex29 
 
28.3(±5.6)   47.5( ±7.1)    0.059 
SF 36-MCS 69.1 (±11)    50 (±26.8)  0.089 
SF 36-PCS 
 
86.6 (±5.2)   67.1 (±26.9)   0.063 
EQ5D  
 
88.3 (±13.2)    65.1 (±21.2)  0.012 
EQ VAS 
 
77.0 (±10.8)   58.0 (±21.9)  0.045 
BDI 
 
6.6 (±6.3)       13.5 (±8.7)  0.105 
Pathologic BDI  
 
N=2   N=6   
 
Values are given as mean, where applicable with SD (± standard deviation).  Significance (p) of the 
group comparison calculated by unpaired t-test.  
 
BMI; Body Mass Index. EASI; Eczema Area and Severity Index. PASI; Psoriasis Area and Severity 
Index. DLQI; Dermatological Life Quality Index. SF 36-MCS; Short Form 36 mental component 
summary. SF 36-PCS; Short Form 36 physical component summary. EQVAS; EQ Visual Analogue 
Scale. EQ5D was calculated by the multiplicative model [31].  BDI; Beck Depression Inventory.   
Education levels defined by the International Standard Classification of Education (ISCED) levels: 
low (lower secondary corresponding <10th grade), medium (upper secondary 10th-12th grade/ 
apprenticeship), high (post-secondary non-university/university education).  
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Table 2: Qualitative Feedback: Main Topics mentioned in Patients’ Feedback  
 
 Topics mentioned Sample answers 
 
 
 
 
 
 
 
 
 
 
 
 
 
Open question about 
general setup and 
holistic approach 
(evaluation sheet,  
n=4 out of 8 in 
intervention group 
returned the 
evaluation sheet) 
• Group setup: 
o meeting individuals with the 
same, life-long experience 
(n=3) 
o exchanging and discussing 
insights of living with the 
chronic skin condition (n=2) 
 
 
 
 
 
 
• Holistic setup: 
o Holistic setup addressed 
the patient`s needs (n=3) 
o Generic Information about 
the skin, lifestyle and the 
disease pathology (n=4) 
o Discussion with 
professionals out of 
multiple disciplines (n=2) 
o Not enough experience 
gained (n=2) 
 
 
 
 
 
 
• Duration of 9 weeks: 
o “Too long-winded” (n=1) 
o Too effortful (n=2) 
o more focus on the impact of 
multidisciplinary aspects on 
the skin than life-style 
intervention (n=1)  
o duration to be shorter or 
longer (n=2) 
 
„Speziell, dass es 
hautmässig noch 
Gleiche oder Ähnliche 
wie mich gibt“ „ 
„Stimmung in der 
Gruppe war/ist sehr 
gut“,   
„Austausch mit 
Gleichgesinnten und 
Fachpersonen“ 
 
 
 
„Inspirationen“ 
„Programm war 
interessant, vielfältig“ 
„verschiedene 
Angebote gut, 
passend, informativ“ 
„generelle Infos 
interessant“ 
„Weiterbildung in 
persönlicher Sache“ 
„Interessant“  
 
 
 
 
 
 
„Mehr über eigene 
Erfahrungen 
sprechen“ 
„zu viel, zu belastend“ 
„entweder kürzer oder 
länger“ 
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Table 3: Qualitative Feedback: Main Topics mentioned in the Open Group 
Feedback Session 
 
Answers to open question about self-experienced burden of disease 
(group feedback session) 
 Topics mentioned 
 
Main concern Sample answers 
Dimension Physical Burden of disease 
Compliance / Therapy 
management 
 
 
 
 
 
 
 
 
 
Daily stress 
 
understanding of the 
skin pathology, need 
for structured 
information on 
therapy 
 
 
 
 
personal coping to 
release daily stress 
 
„ich traue mich mehr, Steroide anzuwenden und habe 
weniger Schuppen auf der Kopfhaut“ 
„Informationen sehr interessant und aufschlussreich“ 
„interessanter Austausch mit den Fachpersonen“ 
„ich habe jetzt viel mehr Informationen zu verschiedenen 
Rückfettungsprodukten erhalten, dass ich viel besser ein 
geeignetes Produkt wählen kann“ 
 
 
 
 
„Meditation angenehm, entspannend“, „ Yoga ruhig und 
angenehm“, „neue Ansichtsweisen bei  Meditation“ 
Dimension Psycho-social Burden of disease 
Self-image 
 
 
 
 
 
 
 
 
 
 
Social vulnerability 
and impact on daily 
life 
 
 
 
reduced self-esteem/ 
shyness/ 
helplessness 
 
 
 
 
 
 
 
 
Fear of being judged 
and rejected because 
of the visibility of 
disease/ 
shamefulness 
„Speziell, dass es hautmässig noch Gleiche oder Ähnliche 
wie mich gibt „, „Man hat andere, mit denen man über die 
Haut und die persönlichen Probleme sprechen kann“, 
„„Zusammenkommen/Austausch mit gleichgesinnten gut“ 
“, „hätte wohl endlos zu diskutieren gegeben“ 
„entlastend, Schulung hat mir die Selbstzweifel und 
psychischen Druck 
 
 
 
  
„sehr entspannend, dass man die Beine nicht verstecken 
und kann kurze Hosen tragen“ „Sport machen ohne dass 
ich mich blossstelle“ 
„sehr erleichternd, dass alle anderen genauso wie ich nach 
dem Sport sich lange eincremen müssen “ 
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Figure 1: Study Flow Chart (AD= atopic dermatitis, Pso= psoriasis)            
  
Analysis 
Allocation 
Assessed for eligibility (n=85) 
Excluded (n=67) 
• Not meeting inclusion criteria (n=2) 
• Declined to participate (n=65) 
 
Allocated to intervention  
(n=9, 7 AD/2 Pso) 
• Received intervention 2x week for 9 
weeks (n=8) 
• Not receiving intervention, no 
baseline data available  
(time constraints) (n= 1 AD) 
Randomized (n= 18, 10 AD/8 Pso)  
Allocated to control 
(n=9, 3 AD/6Pso) 
Lost to follow up 
(n=1 Pso)  
Enrollment 
3 months’ follow-up (post 
intervention) 
 
 
 
6 months’ follow-up 
 
 
9 months’ follow- up 
(end of study) 
 
Analyzed (n=8, 6 AD/2 Pso) 
• Excluded from analysis (not 
receiving intervention/no time 
availability) (n=1) 
Analyzed (n=8, 3 AD/5 Pso) 
• Excluded from analysis (missing 
baseline data (n=1) 
Lost to follow up 
(n=2 Pso)  
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Figure 2: Panel A: DLQI in intervention and control group 
Median DLQI scores at start and at 3-month intervals are shown as boxplot. The right panel shows DLQI 
for the intervention group, the left panel for the control group. No differences were found for DLQI neither 
between start and end of intervention nor for the follow-up (data not shown).  
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Figure 2: Panel B: Skindex29 in intervention and control group 
Median Skindex29 scores at start and at 3-month intervals are shown as boxplot.  The right panel shows 
Skindex29 for the intervention group, the left panel for the control group.  No differences were found for 
Skindex29 neither between start and end of intervention nor for the follow-up (data not shown).  
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Figure 3: Panel A: SF36-MCS in intervention and control group 
Median SF36-MCS scores at start and at 3-month intervals are shown as boxplot.  The right panel shows 
SF36-MCS for the intervention group, the left panel for the control group - No differences were found for 
SF36-MCS neither between start and end of intervention nor for the follow-up (data not shown).  
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Figure 3: Panel B: SF36-PCS in intervention and control group 
Median SF36-PCS scores at start and at 3-month intervals are shown as boxplot.  The right panel shows 
SF36-PCS for the intervention group, the left panel for the control group - No differences were found for 
SF 36-PCS neither between start and end of intervention nor for the follow-up (data not shown).   
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Figure 4: BDI in intervention and control group 
Median BDI scores at start and at 3-month intervals are shown as boxplot.  The right panel shows BDI for 
the intervention group, the left panel for the control group - No differences were found for BDI neither 
between start and end of intervention nor for the follow-up (data not shown). 
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Figure 5: Panel A: EASI in intervention and control group 
Median EASI scores at start and at 3-month intervals are shown as boxplot.  The right panel shows EASI 
for the intervention group, the left panel for the control group - No differences were found for EASI neither 
between start and end of intervention nor for the follow-up (data not shown).  
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Figure 5: Panel B: PASI in intervention and control group 
Median PASI scores at start and at 3-month intervals are shown as boxplot.  The right panel shows PASI 
for the intervention group, the left panel for the control group - No differences were found for PASI neither 
between start and end of intervention nor for the follow-up (data not shown).   
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Median EQ5D scores at start and at 3-month intervals are shown as boxplot. The right panel shows 
EQ5D for the intervention group, the left panel for the control group. No differences were found for EQ5D 
between start and end of intervention nor for the follow-up (data not shown).  
Supplementary Figure 4: EQ VAS in intervention and control group 
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95% Confidence intervals of the score-differences were calculated between baseline and month 3, 
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for each group by a paired t-tests. Significance (p) of the differences between the intervention and the 
control group was calculated by an unpaired t-test.  
Supplementary Figure 6: Paper and pencil version of the DLQI, Skindex29, SF36, EQ VAS, EQ5D, 
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Evaluationsleitfaden 
30.11.2012 
HAUT-TIEF Patientenschulung bei chronischer Psoriasis und atopischem Ekzem 
A prospective, randomized, controlled, multi-center study of the impact of education and stress-reduction 
techniques on psoriasis and eczema 
Name: 
 
Wie finden Sie das Konzept der 
Patientenschulung? 
 
 
 
Konzept gut, muss unbedingt mit Plan erläutert 
werden, weil die Patienten sonst den 
Zeitaufwand falsch einschätzen  
 Zielgruppe. Durch Familie/Verantwortung 
für andere belastete Patienten mittleren 
Alters fanden es am besten. 
 
Wie finden Sie die praktische Durchführung der 
Patientenschulung? 
 
 
 
2h abends unter der Woche mit 15 min 
Wechselzeit dazwischen gut. 
 
Räumlichkeiten: Es wäre professioneller, wenn 
alles an der Rheumaklinik stattfindet um Wege 
zu reduzieren 
Einzelstunden-Feedback 
 
Sport (Michele Mattle) 
 
 
Sehr gut. Beibehalten. Auf 8h. 
 
Yoga (Karin Baechle/Anita Maggi) 
 
 
Bitte Yoga Lehrer aus dem Sport ASUZ besser. 
 
Dermatologische Schulung (PD Hofbauer) 
 
 
Sehr gut. Beibehalten. 
 
Produktschulung „Theorie“ (Prof. Surber über 
Salben und Cremes, Galenik /Dr. Feldmeyer 
über Wirkstoffe) 
 
Prof Surber. Gut und klärend 
Dr. Feldmeyer Wirkstoffe: sollte kürzer, 
didaktischer sein: Viel Studien zu Steroiden, 
Steroidangst, UV-Licht und Gefährdung, 
Auswirkung Salz, Klimatherapie, Kanzerogenität 
Calcineurininhibitoren, und schematische 
Darstellung der Wirkweise. 
 
Produktschulung „Praxis“ (Markus Musholt /Prof. 
Surber/ PD Hofbauer Fragesession) 
 
 
 
Ernährungsberatung (Kirsten Scheuer) 
 
 
 
 
Psychologische Schulung Dermatopsychologie + 
Alkohol/Sucht (Susanne Döbbel) 
 
 
 
Mindfulness Meditation (Beatrice Heller) 
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Philosophische Session (Prof. Thurnherr) 
 
 
 
 
Offen: 
 
 
 
 
 
Was hat Ihnen generell gefallen? 
 
 
 
 
 
 
 
 
 
 
Was würden Sie ändern? 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1: Evaluation sheet: Patients’ written feedback after 
intervention 
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Topic Trainer Number 
 
of 
Duration 
 
1 session 
Total 
 
duration 
1. Information on skin disease 
conditions 
 
1.a. Information session about skin 
diseases. 
 
 
1.b. Information session about skin care
“hands-on” 
 
 
Dermatologist 
 
 
Pharmacist and nurse 
specialized in skin 
care 
 
 
2 
 
 
1+ 2 
 
 
60 min 
 
 
60min 
120min 
 
 
2h 
 
 
3h 
2. Stress management 
 
 
2.a. Physical training and fitness 
assessment 
 
2.b. Yoga 
 
2.c. Mindfulness meditation 
 
 
 
Sports teacher 
Yoga teacher 
Mindfulness 
teacher 
 
 
 
9 
 
8 
 
3 
 
 
 
60 min 
 
60 min 
 
120min 
 
 
 
9h 
 
8 h 
 
6h 
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3.  Information sessions on life style 
factors 
 
and psycho dermatology 
 
3.a. Nutrition 
 
 
3.b. Sleep hygiene 
 
 
3. d. Smoking cessation (individual) 
 
 
3.e. Substance abuse 
 
 
3.f. Practical philosophy 
3.g. Psycho dermatology 
 
 
 
 
Dietician  
 
 
Psychiatrist/Psyc
hologist  
 
Psychiatrist  
 
 
Psychiatrist 
/Psychologist  
 
Philosopher  
 
 
Psychiatrist/ 
Psychologist  
 
 
 
 
 
2 
 
 
1 
 
 
Optional 
 
 
1 
 
 
1 
 
 
1 
 
 
 
 
60 min 
 
 
60min 
 
 
 
 
 
60 min 
 
 
 
120 min 
 
 
60 min 
 
 
 
 
2 h 
 
 
1h 
 
 
 
 
 
1h 
 
 
 
2h 
1h 
4. Feedback 
 
 
 
 
 
 
Dermatologist 
 
 
 
 
 
 
 
60 min 
 
 
1 h 
   
Total 36h  
 
Supplementary Figure 2: Content of the program 
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Supplementary Figure 3: EQ5D in intervention and control group 
Median EQ5D scores at start and at 3-month intervals are shown as boxplot. The right panel shows 
EQ5D for the intervention group, the left panel for the control group. No differences were found for EQ5D 
between start and end of intervention nor for the follow-up (data not shown).  
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Supplementary Figure 4: EQ VAS in intervention and control group 
Median EQ VAS scores at start and at 3-month intervals are shown as boxplot.  The right panel shows 
EQ VAS for the intervention group, the left panel for the control group - No differences were found for EQ 
VAS neither between start and end of intervention nor for the follow-up (data not shown).  
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p= 0.63 p= 0.61 
p= 0.62 p= 0.63 
p= 0.95 p= 0.87 
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p= 0.07 p= 0.43 
p= 0.11 p= 0.40 
p= 0.22 p= 0.41 
p= 0.07 p= 0.84 
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Supplementary Figure 5: 95% CI score differences for DLQI, Skindex29, SF36-
MCS, SF36-PCS, EQ VAS, EQ5D, EASI, PASI, BDI.            
95% Confidence intervals of the score-differences were calculated between baseline and month 3, 
respectively between baseline and month 9 for intervention and control groups. 95% CI were calculated 
for each group by paired t-tests. Significance (p) of the differences between the intervention and the 
control group was calculated by an unpaired t-test.  
 
 
  
p= 0.07 p= 0.93 
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Supplementary Figure 6: Paper and pencil version of the DLQI, Skindex29, SF36, 
EQ VAS, EQ5D, BDI. 
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